- Home
- MAMA vs ADCT Comparison
MAMA vs ADCT Comparison
Compare MAMA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- ADCT
- Stock Information
- Founded
- MAMA 2010
- ADCT 2011
- Country
- MAMA United States
- ADCT Switzerland
- Employees
- MAMA N/A
- ADCT N/A
- Industry
- MAMA Specialty Foods
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- MAMA Consumer Staples
- ADCT Health Care
- Exchange
- MAMA Nasdaq
- ADCT Nasdaq
- Market Cap
- MAMA 290.7M
- ADCT 224.3M
- IPO Year
- MAMA N/A
- ADCT 2020
- Fundamental
- Price
- MAMA $7.74
- ADCT $2.08
- Analyst Decision
- MAMA Strong Buy
- ADCT Strong Buy
- Analyst Count
- MAMA 4
- ADCT 5
- Target Price
- MAMA $10.50
- ADCT $8.00
- AVG Volume (30 Days)
- MAMA 483.1K
- ADCT 1.7M
- Earning Date
- MAMA 12-16-2024
- ADCT 11-07-2024
- Dividend Yield
- MAMA N/A
- ADCT N/A
- EPS Growth
- MAMA N/A
- ADCT N/A
- EPS
- MAMA 0.08
- ADCT N/A
- Revenue
- MAMA $116,468,000.00
- ADCT $70,717,000.00
- Revenue This Year
- MAMA $18.91
- ADCT $6.58
- Revenue Next Year
- MAMA $12.69
- ADCT $11.78
- P/E Ratio
- MAMA $89.73
- ADCT N/A
- Revenue Growth
- MAMA 17.20
- ADCT N/A
- 52 Week Low
- MAMA $4.17
- ADCT $1.45
- 52 Week High
- MAMA $9.98
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- MAMA 33.00
- ADCT 44.05
- Support Level
- MAMA $7.19
- ADCT $1.93
- Resistance Level
- MAMA $7.74
- ADCT $2.18
- Average True Range (ATR)
- MAMA 0.54
- ADCT 0.40
- MACD
- MAMA -0.26
- ADCT -0.02
- Stochastic Oscillator
- MAMA 8.27
- ADCT 10.65
About MAMA Mama's Creations Inc.
Mama`s Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in over 8,400 grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.